Edgewise Therapeutics Inc
EWTXHealthcare|Biotechnology|USA
$45.41
-2.94 (-6.08%)
Tangible Book
$4.59
Earnings Power
$4.34
Clinical Trials (18)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06347159 A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) | Hypertrophic Cardiomyopathy | P2 | Active | 100 | Open-label | EDG-7500, EDG-7500 |
| NCT05291091 Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | Becker Muscular Dystrophy | P2 | Active | 244 | RCT, Double-blind | Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo |
| NCT05540860 A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) | Duchenne Muscular Dystrophy | P2 | Active | 76 | RCT, Double-blind | Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo |
| NCT06100887 Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy | Duchenne Muscular Dystrophy | P2 | Active | 43 | RCT, Double-blind | Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Placebo |
| NCT07177066 A Study of EDG-15400 in Healthy Adults | Healthy Adults | P1 | Recruiting | 108 | RCT, Double-blind | EDG-15400, Placebo |
| NCT07324616 A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment | Hepatic Impairment (HI) | P1 | Recruiting | 32 | Open-label | EDG-7500 |
| NCT05257473 Defining Endpoints in Becker Muscular Dystrophy | Becker Muscular Dystrophy, Muscular Dystrophies | Active | 80 | — | — | |
| NCT06066580 Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | Becker Muscular Dystrophy | P2 | By Invite | 260 | Open-label | Sevasemten |
| NCT04585464 A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults | Healthy Volunteer, Becker Muscular Dystrophy | P1 | Completed | 127 | RCT, Double-blind | EDG-5506, Placebo |
| NCT06738836 A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500 | Healthy Volunteer | P1 | Completed | 8 | Open-label | [14C]-EDG-7500 |
| NCT05730842 Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers | Healthy Volunteer, Muscular Dystrophies | P1 | Completed | 15 | Open-label | EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous |
| NCT05160415 A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy | Becker Muscular Dystrophy | P1 | Completed | 12 | Open-label | Sevasemten |
| NCT06916897 A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers | Healthy Subjects | P1 | Completed | 42 | RCT, Open-label | sevasemten, Verapamil |
| NCT06011317 A Study of EDG-7500 in Healthy Adults | Healthy Subjects | P1 | Completed | 84 | RCT, Double-blind | EDG-7500, Placebo |
| NCT05492734 A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling | Muscular Dystrophies | P1 | Completed | 10 | Open-label | EDG-5506 |
| NCT07034768 A Study to Evaluate EDG-7500 in People With Renal Impairment | Renal Impairments | P1 | Completed | 37 | Open-label | EDG-7500 |
| NCT07456059 A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults | Healthy Adult Participants | P1 | Not Yet Recruiting | 24 | Open-label | EDG-7500 |
| NCT04349566 Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases | Becker Muscular Dystrophy, McArdle Disease | Completed | 36 | — | — |